key: cord-0802361-ppd2pwtc authors: Forestal, Roberto Louis; Pi, Shih‐Ming title: A hybrid approach based on ELECTRE III‐genetic algorithm and TOPSIS method for selection of optimal COVID‐19 vaccines date: 2021-11-15 journal: Journal of Multi-Criteria Decision Analysis DOI: 10.1002/mcda.1772 sha: c2099c225525bcbc9bc18990a05bd6c4590442e2 doc_id: 802361 cord_uid: ppd2pwtc COVID‐19 pandemic poses unprecedented challenges to the world health system, prompting academics and health professionals to develop appropriate solutions. Researchers reported different COVID‐19 vaccines introduced by institutions and companies around the globe, which are at different stages of development. However, research developing an integrated framework for selecting and ranking the optimal potential vaccine against COVID‐19 is minimal. This paper aimed to fill this gap by using a hybrid methodology based on ELimination Et Choice Translating REality III (ELECTRE III)–Genetic Algorithm (GA) and Technique of Order Preference Similarity to the Ideal Solution (TOPSIS) approach to select the optimal SARS‐CoV‐2 vaccine. ELECTRE III method yields a fathomable analysis of the concordance index, while GA is known for its ability to disaggregate decision‐making preferences from holistic decisions. TOPSIS is preferred for picking an ideal and an anti‐ideal solution. Thus, combining ELECTRE III‐GA and TOPSIS is considered the best model to assess vaccines against the pandemic. The results confirm that the best vaccines rely on a high level of safety, efficacy, and availability. Our developed evaluation framework can help healthcare professionals and researchers gain research information and make critical decisions regarding potential vaccines against the disease. effectively solved using the integration of Entropy and TOPSIS. The linear support vector machine (SVM) classifier is selected as the best diagnosis model for COVID-19 with the closeness coefficient value of 0.9899 for their case study data. Furthermore, the proposed methodology has solved the significant variance for each criterion in terms of ideal best and worst best value and the issue when specific diagnosis models have the same ideal best value. However, our research acknowledges a substantial gap in the use of MCDM to select COVID-19 vaccines, as noted by Abdelwahab et al. (2021) , despite the fact that Hezam et al. (2021) highlighting the importance of vaccine classification uses a neutrosophic analytic hierarchy process (AHP) and TOPSIS method to rank COVID-19 vaccine alternatives based on priority groups. Consequently, much of the existing literature focuses on the vaccine distribution process (Jakhar et al., 2021) instead of considering optimal vaccination approaches (Moore et al., 2021) . ELimination Et Choice Translating Reality III (ELECTRE III) and genetic algorithm (GA) have reportedly outperformed common approaches in selecting optimal solutions while TOPSIS confirms its effectiveness in measuring the relative performance for each alternative (Aiello et al., 2013; Chen, 2021; Leyva-L opez & Fernández-González, 2003) . Therefore, using a hybrid methodology based on ELECTRE-GA and TOPSIS approach can provide valuable insights into the optimised scenarios building (Marchetti & Wanke, 2020; Rohaninejad et al., 2015; Vafaeinejad, 2016) . Concerning the motivation, our analysis also contributes to emerging literature studying COVID-19 vaccines, their safety, and effectiveness. The remainder of the paper is structured as follows. Section 2 details the literature review. Section 3 presents the methodology used, including data selection and decision-making assessment. Section 4 and Section 5 present the empirical case study as well as results and discussion. Section 6 discusses managerial implications, while the final Section 7 concludes the analysis and elaborates on the limitations of the paper. The novel COVID-19 pandemic caused by SARS-CoV-2 is a publichealth emergency of international concern, thus calling for the development of a safe and effective vaccine to protect against the infection. It is essential to assess people's intention to be vaccinated. Studies such as Faasse and Newby (2020) and Head et al. (2020) conducted an online survey to examine the role of perceived risk, media coverage, and vaccination intentions among thousands of respondents. Findings revealed that the majority of interviewees were at least moderately concerned about a widespread outbreak. Worrying about the epidemic and closely monitoring media coverage were consistent forecasting parameters of health protection behaviours and vaccination intentions. With growing demand, the availability of a COVID-19 vaccine is touted as the solution to controlling the current COVID-19 pandemic, reducing the number of infections and deaths, and facilitating the resumption of our previous lifestyle (Abdullahi et al., 2021; Begum et al., 2021) . Scholars reported that many research institutions and pharmaceutical companies have already embarked on the race to develop COVID-19 vaccines, which involved the adaptive immune system. Their analysis recoursed to immunoinformatics and advocated a sequence analysis of the pathogenic strains of SARS-CoV-2 to design vaccine candidates. These vaccine candidates may provide meaningful, timely directives for an effective vaccine against SARS-CoV-2 Kumar et al., 2021; Oyarzun et al., 2021) . Moreover, SARS-CoV-2 spike glycoprotein followed by epitopes' use in constructing a multi-epitope peptide vaccine construct (MEPVC) is also an attractive candidate for a vaccine, antibodies, and inhibitor development because of the many roles it plays in attachment, fusion, and entry into the host cell. The MEPVC revealed robust host immune system simulation with high immunoglobulins, cytokines, and interleukins (Enayatkhani et al., 2021; Saha et al., 2021) . Other researchers designed and presented different kinds of vaccines against the novel coronavirus. For instance, Khurana et al. (2021) and Malabadi et al. (2021) proposed a development framework of a potential COVID-19 vaccine based on nanotechnology. They highlight the utility of nanomedicine in alleviating the COVID-19 health crisis. In addition, it is also crucial to mention that previous researchers argued the need to optimise SARS-CoV-2 vaccine confidence, availability, and efficacy. For example, Mehrotra et al. (2021) provide a set of clinical endpoints based on clinical and statistical reasoning to facilitate a harmonised assessment and comparison of the efficacy of novel coronavirus vaccines. Ensuring public confidence in vaccine safety and effectiveness is also crucial to facilitate uptake. Bartsch et al. (2020) apply a computational model of the U.S. simulating the spread of COVID-19 coronavirus and vaccination and reveal that the vaccine efficacy has to be at least 60% when vaccination coverage is 100%. Moreover, to extinguish an ongoing epidemic, the vaccine efficacy has to be at least 60% when coverage is 100% and at least 80% when coverage drops to 75% to reduce the peak by 85-86%, 61-62%, and 32% when vaccination occurs after 5, 15, and 30% of the population, respectively, have already been exposed to COVID-19 coronavirus. A vaccine with an efficacy between 60 and 80% could still obviate the need for other measures under certain circumstances such as much higher, and in some cases, potentially unachievable, vaccination coverages. proposed where TOPSIS is applied for the benchmarking and ranking purpose while Entropy is used to calculate the weights of criteria. The results revealed that the benchmarking and selection problems associated with COVID-19 diagnosis models could be effectively solved using the integration of Entropy and TOPSIS. The linear SVM classifier is selected as the best diagnosis model for COVID-19 with a closeness coefficient value of 0.9899 for their case study data. Furthermore, the proposed methodology has solved the significant variance for each criterion in terms of ideal best and worst best value, besides issues when specific diagnosis models have the same ideal best value. Although much work has been done on the novel coronavirus, obtaining an integrated solution to limit the current COVID-19 disease remains challenging. Many studies conducted so far resulted in the urgent need to develop vaccines. Still, less has proposed a comprehensive framework to select and rank those potential vaccines candidates. Our research aims to apply a hybrid methodology based on ELECTRE III-Genetic Algorithm and the TOPSIS approach to select and outclass the best SARS-COV-2 vaccines. This section discusses one possible methodology for assessing COVID-19 candidate vaccines using indicators. Following Aiello et al. (2013) and Majumder, Biswas, and Majumder et al. (2020) , our research applied ELECTRE-GA and TOPIS approaches to selected and outranked candidate vaccines in clinical evaluation aiming at providing active acquired immunity to the novel coronavirus. Identifying appropriate criteria for COVID-19 candidate vaccines is essential for reliable outcomes. We examined several criteria sets pro- The FDA has issued guidance for the industry on the steps required for developing and ultimately licensing vaccines to prevent COVID-19-these are the same rigorous safety standards required for all vaccines. We imply that data from animal and human studies support no apparent risk of enhanced disease in vaccines by safety. Moreover, we also imply a lack of significant disease enhancement risk supported by clinical and/or pre-clinical data from relevant/suitable animal model(s) and unexpected severe findings that could require more investigations. To calculate vaccine safety, we use a crude ratio from Whelan (2009) . This percentage is defined as the number of subjects exposed to a vaccine and experiencing a particular adverse event (such as fever, headaches, muscle pain), n, divided by the total number of subjects exposed to the vaccine, N, regardless of the duration of follow-up: Safety rate SR ð Þ¼100 À CR An efficacious COVID-19 vaccine could reduce the likelihood of infection of an individual, severity of disease in an individual, or degree of transmission within a population. In other words, it refers to the percentage reduction in the incidence of the disease in a vaccinated group compared to an unvaccinated group under optimal conditions (Nichols et al., 2018) . We use the following equation from Orenstein et al. (1985) to estimate vaccine efficacy: where ARU is the attack rate of COVID-19 disease in the unvaccinated population, and ARV relates to the attack rate of the disease in the vaccinated population. Once the efficacy of a vaccine has been asserted, determining its effectiveness is essential to establish the vaccine's uptake. Efficacy determines if the vaccine works, whereas effectiveness monitors the benefits of vaccination for the community. Vaccine effectiveness refers to preventing COVID-19 disease depending on its potency and proper administration to individuals capable of responding (Andrew & McNeil, 2021) . It can be measured by considering the percentage of COVID-19 cases vaccinated (PCV), and the proportion of the population vaccinated (PPV) following Cohen et al. (2007) . Stability data are sufficient to assure delivery of dose to be tested. The stability of vaccines has a significant impact on the success of immunisation programmes worldwide. Optimising the use of vaccines depends heavily on maintaining optimal storage conditions. A vaccine is now expected to remain stable at standard refrigerator tempera- However, some vaccines are sensitive to freezing, some to heat and others to light. Therefore, replacing a traditional models of vaccine stability with a version that yielded cost-saving appears to be more appropriate in appraising vaccine stability as Lee et al. (2017) proposed. This refers to the relative stability (r) of the vaccine i, which is the ratio between the minimum costs associated with other vaccines and vaccine i. PC, TC, and SC refer to procurement, transport, and storage costs, respectively. The proposed set of indicators is organised into measurement units and information sources, as shown in Table 1 . An evaluation of coronavirus vaccine candidates has been performed using two multi-criteria approaches. The first one is based on ELECTRE III, whose first version was proposed by Bernard Roy The GA generates an initial population conforming to decision variables which are then converted into inter-criteria parameters (see Figure 1 ). Each element in the population is evaluated by its fitness, which concerns the set of inter-criteria parameters that better represent the decision-making's preference when the set is used to construct the fuzzy outranking relation, then used in a multi-criteria classification. Once the GA has passed through all F I G U R E 1 Simple genetic algorithm adapted from Sheppard (2017) the generations, the final result presents a set of inter-criteria parameters. When used by ELECTRE III generates rankings similar or identical to the entry ranking defined by the decision-makers (Carrillo et al., 2017) . We consider the following steps to derive GA intercriteria parameters for our proposed ELECTRE III-GA model. Phase 3: Consider the inter-criteria parameters as output data. The outcomes of GA show the best population. This results in different sets of inter-criteria parameters, which generates a ranking corresponding to the preferences of the DM. The second multi-criteria approach we use to evaluate coronavirus vaccine candidates is TOPSIS. Introduced in 1981, TOPSIS is based on picking an ideal and an anti-ideal solution and comparing the distance of each one of the alternatives to those (Chen & Hwang, 1992) . As described previously, the search to find a vaccine against COVID-19 consists of two subprocesses: selecting and ranking problems. In The next instance of the ranking problem discusses an empirical study of the following actual selection and ranking problem. Using the original ELECTRE method, performance matrix, thresholds, weights (relative importance of the criteria), and final ranking were calculated and presented in this subsection. The DM was supported in defining its preferences and uncertainties through the indifference threshold (q), the preference threshold (p), and the veto threshold (v) for all five criteria by using a linear format. We define two columns of numeric values for each threshold, one for the slope (label beginning by alpha) and another for the interception (label beginning by beta), as shown in Table 2 . Evaluation and prioritisation of COVID-19 candidate vaccines developed by WHO are considered here. We complete the data preparation by imposing a direction of evaluation for each criterion and a direction of definition for each threshold, as shown in Table 3 . All applicants were also evaluated by the experts using the criteria and scale. All criteria were treated as quantitative ones. Based on the additional information pointed out, we applied ELECTRE III to construct a fuzzy outranking relation. The credibility matrix indicates the reliability of the outranking hypothesis. Suppose the concordance index is greater than or equal to the discordance index for all criteria. In that case, the degree of credibility is equal to the concordance index. If the concordance index is strictly lower than the discordance index, then the degree of credibility is equal to the concordance index lowered to the importance of these discor- A preference score of 21 is shared between labels A15, A17, and A25, while alternatives A27, A40, and A46 are preferred 15 times compared to others (Table 4) . From the ELECTRE III-GA model, we extracted 15 actions based on Preference (P > 30) and Non-preference (NP < 15), as presented in Table 5 . Then, we used Excel Spreadsheet to determine the weighted normalised decision matrix and Python compiler to plot the Ideal and anti-ideal solutions (Figure 3 ). Although we have shown an essential contribution to the literature, it is important to notice some limitations that future research can consider. First, the compilation of 108 vaccine alternatives following the WHO framework was systematic. Still, our assessment of the inclusion criteria is based on our subjective judgement. Therefore, some critical criteria such as supply chain, environment, and race are missing in this review. Future work can extend this framework by considering other criteria and other databases to perform assessment and evaluation on COVID-19 vaccines. A second limitation is sensitivity analysis. A sensitivity analysis is essential to test the robustness of the results obtained from the decision model by varying the values of the weights and thresholds and observing the effect on the outcome. Subsequent work may consider adding a robustness test to check the overall validity of this model. These limitations can provide future research avenues and can step on the contributions established by this paper. A novel vaccine selection decision-making model (VSDMM) for COVID-19 Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: Prospects and challenges A non dominated ranking multi objective genetic algorithm and electre method for unequal area facility layout problems Influenza vaccination and the evolution of evidence-based recommendations for older adults: A Canadian perspective The need for novel approaches in assessing the value of COVID-19 vaccines Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention Pain treatment evaluation in COVID-19 patients with hesitant fuzzy linguistic multicriteria decision-making Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development Deriving parameters and preferential model for a total order in ELECTRE III Effects of the entropy weight on TOPSIS Fuzzy multiple attribute decision making methods Lecture notes in economics and mathematical systems COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: A bibliometric analysis based on VOSviewer Performance of fuzzy multi-criteria decision analysis of emergency system in covid-19 pandemic. an extensive narrative review Vaccine effectiveness estimates How the use of vaccines outside the cold chain or in controlled temperature chain contributes to improving immunization coverage in low-and middle-income countries (LMICs): A scoping review of the literature Stability of vaccines Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: An in silico study Public perceptions of covid-19 in australia: perceived risk, knowledge, health-protective behaviors, and vaccine intentions ELECTRE methods. In S Multiple criteria decision analysis A national survey assessing SARS-CoV-2 vaccination intentions: Implications for future public health communication efforts COVID-19 vaccine: A neutrosophic MCDM approach for determining the priority groups COVID-19 vaccination prioritization for persons with severe mental illness Role of nanotechnology behind the success of mRNA vaccines for COVID-19 Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework Economic impact of thermostable vaccines A new method for group decision support based on ELECTRE III methodology Application of new topsis approach to identify the most significant risk factor and continuous monitoring of death of covid-19 Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19) Efficiency of the rail sections in Brazilian railway system, using TOPSIS and a genetic algorithm to analyse optimized scenarios Clinical endpoints for evaluating efficacy in covid-19 vaccine trials Benchmarking methodology for selection of optimal covid-19 diagnostic model based on entropy and topsis methods Modelling optimal vaccination strategy for SARS-CoV-2 in the UK Towards understanding socially influenced vaccination decision making: An integrated model of multiple criteria belief modelling and social network analysis Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network) Field evaluation of vaccine efficacy A proteome-wide immunoinformatics tool to accelerate t-cell epitope discovery and vaccine design in the context of emerging infectious diseases: an ethnicity-oriented approach A hybrid multi-objective genetic algorithm based on the ELECTRE method for a capacitated flexible job shop scheduling problem Multicriteria methodology for decision aiding Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches An integrated fuzzy DEMATEL, TOPSIS, and ELECTRE approach for evaluating knowledge transfer effectiveness with reference to GSD project outcome Capacity evaluation of diagnostic tests for COVID-19 using multicriteria decision-making techniques Genetic algorithms with python Cropping pattern optimization by using of TOPSIS and genetic algorithm based on the capabilities of GIS Mortality in Ireland at advanced ages A hybrid approach based on ELECTRE III-genetic algorithm and TOPSIS method for selection of optimal COVID-19 vaccines The authors are grateful to the anonymous referees for their most helpful suggestions that have improved the quality and legibility of this article. The authors declare no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.T A B L E 6 Final ranking for the Covid-19 vaccines selection problem